{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:17:25Z","timestamp":1765484245678,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009395","name":"CancerCare Manitoba Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017552","name":"University of Manitoba College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.tranon.2021.101203","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:31:24Z","timestamp":1629160284000},"page":"101203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo"],"prefix":"10.1016","volume":"14","author":[{"given":"Mark W","family":"Nachtigal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Musaphir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon D","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101203_bib0001","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume":"4","author":"Global Burden of Disease Cancer","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tranon.2021.101203_bib0002","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2021.101203_bib0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.tranon.2021.101203_bib0004","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4161\/auto.9120","article-title":"1-O-Hexadecyl-2-O-methyl-3-O-(2\u2032-acetamido-2\u2032-deoxy-beta-d-glucopyranosyl)-sn-gly cerol (Gln) induces cell death with more autophagosomes which is autophagy-independent","volume":"5","author":"Jahreiss","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.tranon.2021.101203_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-017-0538-9","article-title":"Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells","volume":"36","author":"Moraya","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0006","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1039\/C6MD00328A","article-title":"Design, synthesis and evaluation of cytotoxic properties of bisamino glucosylated antitumor ether lipids against cancer cells and cancer stem cells","volume":"7","author":"Ogunsina","year":"2016","journal-title":"Medchemcomm"},{"key":"10.1016\/j.tranon.2021.101203_bib0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1139\/O08-147","article-title":"A glycosylated antitumor ether lipid kills cells via paraptosis-like cell death","volume":"87","author":"Samadder","year":"2009","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.tranon.2021.101203_bib0008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2014.03.057","article-title":"Cytotoxic properties of d-gluco-, d-galacto- and d-manno-configured 2-amino-2-deoxy-glycerolipids against epithelial cancer cell lines and BT-474 breast cancer stem cells","volume":"78","author":"Samadder","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tranon.2021.101203_bib0009","series-title":"Carbohydrates in Drug Design and Discovery","article-title":"Synthetic glycosylated ether glycerolipids as anticancer agents","author":"Arthur","year":"2015"},{"key":"10.1016\/j.tranon.2021.101203_bib0010","first-page":"2291","article-title":"The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1","volume":"23","author":"Samadder","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0011","first-page":"375","article-title":"Final evaluation of a phase II study on the effect of edelfosine (an Ether Lipid) in advanced non-small-cell bronchogenic carcinoma","volume":"15","author":"Drings","year":"1992","journal-title":"Onkologie"},{"key":"10.1016\/j.tranon.2021.101203_bib0012","first-page":"2159","article-title":"Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide","volume":"17","author":"Fujiwara","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0013","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/1389200023337225","article-title":"Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (Edelfosine), a proapoptotic agent in tumor cells","volume":"3","author":"Gajate","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tranon.2021.101203_bib0014","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1871520614666140309231144","article-title":"Glycosylated antitumor ether lipids: activity and mechanism of action","volume":"14","author":"Arthur","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.tranon.2021.101203_bib0015","first-page":"3809","article-title":"An active endocytosis pathway is required for the cytotoxic effects of glycosylated antitumor ether lipids","volume":"31","author":"Samadder","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0016","doi-asserted-by":"crossref","first-page":"15288","DOI":"10.3390\/molecules181215288","article-title":"Structure activity relationships of N-linked and diglycosylated glucosamine-based antitumor glycerolipids","volume":"18","author":"Ogunsina","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.tranon.2021.101203_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/ol006783a","article-title":"Synthesis and growth inhibitory properties of glucosamine-derived glycerolipids","volume":"3","author":"Yang","year":"2001","journal-title":"Org. Lett."},{"key":"10.1016\/j.tranon.2021.101203_bib0018","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1021\/ol991211f","article-title":"Convergent C-glycolipid synthesis via the Ramberg-Backlund reaction: active antiproliferative glycolipids","volume":"1","author":"Yang","year":"1999","journal-title":"Org. Lett."},{"key":"10.1016\/j.tranon.2021.101203_bib0019","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.jmedchem.6b01773","article-title":"Replacing d-glucosamine with its l-enantiomer in glycosylated antitumor ether lipids (GAELs) retains cytotoxic effects against epithelial cancer cells and cancer stem cells","volume":"60","author":"Ogunsina","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tranon.2021.101203_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030566","article-title":"Syntheses of l-Rhamnose linked amino glycerolipids and their cytotoxic activities against human cancer cells","volume":"25","author":"Ogunsina","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.tranon.2021.101203_bib0021","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/nprot.2006.328","article-title":"Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients","volume":"1","author":"Shepherd","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tranon.2021.101203_bib0022","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2174\/1871520614666140309223603","article-title":"A fluorescent alkyllysophospholipid analog exhibits selective cytotoxicity against the hormone-insensitive prostate cancer cell line PC3","volume":"14","author":"Samadder","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.tranon.2021.101203_bib0023","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygyno.2015.05.040","article-title":"In vivo tumor growth of high-grade serous ovarian cancer cell lines","volume":"138","author":"Mitra","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2021.101203_bib0024","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101203_bib0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","volume":"49","author":"Wang","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tranon.2021.101203_bib0026","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011408","article-title":"Copy number analysis identifies novel interactions between genomic loci in ovarian cancer","volume":"5","author":"Gorringe","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tranon.2021.101203_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2020.11.051","article-title":"Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells","volume":"500","author":"Bungsy","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2021.101203_bib0029","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41416-021-01317-w","article-title":"Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer","volume":"124","author":"Lepage","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101203_bib0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ygyno.2021.02.038","article-title":"Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples","volume":"161","author":"Morden","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2021.101203_bib0031","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-020-14551-2","article-title":"A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity","volume":"11","author":"Nelson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2021.101203_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006707","article-title":"The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples","volume":"13","author":"Penner-Goeke","year":"2017","journal-title":"PLos Genet."},{"key":"10.1016\/j.tranon.2021.101203_bib0033","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/386623a0","article-title":"Genetic instability in colorectal cancers","volume":"386","author":"Lengauer","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101203_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tig.2007.11.006","article-title":"Defining 'chromosomal instability","volume":"24","author":"Geigl","year":"2008","journal-title":"Trends Genet."},{"key":"10.1016\/j.tranon.2021.101203_bib0035","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/ERC-17-0187","article-title":"Role of chromosomal instability in cancer progression","volume":"24","author":"McClelland","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tranon.2021.101203_bib0036","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4161\/cc.8.20.9690","article-title":"Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy","volume":"8","author":"McClelland","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tranon.2021.101203_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9110151","article-title":"Evolving therapeutic strategies to exploit chromosome instability in cancer","volume":"9","author":"Thompson","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2021.101203_bib0038","doi-asserted-by":"crossref","first-page":"R285","DOI":"10.1016\/j.cub.2010.01.034","article-title":"Mechanisms of chromosomal instability","volume":"20","author":"Thompson","year":"2010","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tranon.2021.101203_bib0039","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101203_bib0040","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1158\/1078-0432.CCR-08-0243","article-title":"Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model","volume":"14","author":"Mabuchi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101203_bib0041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0000000000000592","article-title":"Latest clinical evidence of maintenance therapy in ovarian cancer","volume":"32","author":"Walsh","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:20:00Z","timestamp":1761844800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1936523321001959"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101203","relation":{},"ISSN":["1936-5233"],"issn-type":[{"type":"print","value":"1936-5233"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101203"}}